All stock lists
Danimer Scientific, Inc. (OTC:DNMR)
US · Delayed Price · Currency is USD
Basic Materials · Chemicals - Specialty
$0.35+$0.00 (+0.00%)
Market cap
$1.06M
Insider Score
Health Score
Analyst consensus
Listed since
May 28, 2020
Website
Insider Score
––Not scored
DNMR Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Weak
From DNMR’s reported statements · Q3 2024 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $37.4M
- Net income
- -$111.2M
- Net margin
- -297.1%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $413.0M
- Cash
- $22.2M
- Debt / equity
- 1.95
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $69.9M
- Current liabilities
- $21.3M
- Current ratio
- 3.28
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$29.1M
- Free cash flow
- -$38.5M
- FCF margin
- -103.0%
Dilution & runway4 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 119.7M
- Share growth (1y)
- 17.3%
- Cash runway
- 9 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
DNMR Income Statement
| Fiscal Period | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
| Revenue | $8.63 M | $7.63 M | $10.22 M | $10.95 M | $10.95 M | $12.87 M |
| Revenue Growth (YoY) | -21.17 % | -40.71 % | -14.27 % | -28.58 % | 4.79 % | 1.28 % |
| Cost of Revenue | $15.95 M | $14.53 M | $18.92 M | $19.54 M | $18.68 M | $19.43 M |
| Gross Profit | -$7.32 M | -$6.90 M | -$8.70 M | -$8.59 M | -$7.74 M | -$6.57 M |
| SG&A Expense | $6.86 M | $6.75 M | $6.52 M | $17.85 M | $16.55 M | $16.84 M |
| R&D Expense | $4.58 M | $5.11 M | $3.31 M | $7.58 M | $6.88 M | $7.71 M |
| Operating Expenses | $11.51 M | $12.43 M | $9.83 M | $25.38 M | $23.50 M | $24.55 M |
| Operating Income | -$18.82 M | -$19.33 M | -$18.52 M | -$31.03 M | -$31.24 M | -$31.12 M |
| Pretax Income | -$21.84 M | -$22.66 M | -$27.26 M | -$39.43 M | -$39.69 M | -$39.30 M |
| Tax Provision | $2.00 K | $2.00 K | $2.00 K | $2.00 K | $468.00 K | -$61.00 K |
| Net Income | -$21.84 M | -$22.66 M | -$27.26 M | -$39.43 M | -$40.16 M | -$39.24 M |
| EPS (Basic) | -$0.18 | -$0.19 | -$0.26 | -$0.39 | -$0.39 | -$0.38 |
| EPS (Diluted) | -$7.20 | -$0.19 | -$0.26 | -$0.39 | -$0.39 | -$0.38 |
| Shares Outstanding | 119.71 M | 116.47 M | 103.97 M | 102.14 M | 102.03 M | 101.94 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.